Theravance Biopharma Q2 net loss turns to USD 5.9 million; revenue rises 11% to USD 20.7 million YoY
Theravance Biopharma reported a Q2 GAAP net loss of USD 5.9 million, a swing from a profit in the prior year, despite an 11% increase in revenue to USD 20.7 million, primarily from the Viatris collaboration. The company also saw reduced R&D and SG&A …